MoveSurge

FDA will miss its Nov. 22, 2026 target date for Savara’s molgramostim inhalation solution application; review continues with no new date set

Observed price moves

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.

Share